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Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53S52CTL speciﬁc for the atypical CMV epitopes revealed that the
avidity was similar to that of CMVpos CTL recognizing
typical epitopes (mean: 300pM), but 30x more avid than
paired CMVpos CTL recognizing atypical epitopes (P<0.05).
TCR sequencing performed on T-cells speciﬁc for typical
(CMVpos) and atypical (CMVpos,CMVneg, and CB) epitopes
revealed that CMVpos donor cCTL recognizing typical epi-
topes were less polyclonal (P¼0.02). To address the concern
that atypical epitopes might not be naturally presented by
CMV-infected cells and therefore not expanded in CMVpos
donors in response to virus infection, we tested whether
cCTL generated using CMV-infected ﬁbroblasts would
recognize the same epitopes. CMVpos cCTL recognized
typical epitopes while CB/CMVneg cCTL recognized only
atypical epitopes, suggesting that the epitopes are naturally
processed/presented by APCs. Using deep T-Cell receptor
(TCR) sequencing we identiﬁed TCRs recognizing typical and
atypical epitopes. When we searched for these sequences in
unmanipulated cord blood units, ﬁve different TCRs recog-
nizing atypical epitopes were found in 5/5 CB units whereas
of 22 NLV sequences, only 1 sequence was found in 1/5 cord
blood units suggesting that T-Cells recognizing atypical
epitopes are more prevalent during the primary infection
and are later replaced by T-Cells recognizing typical epi-
topes. These results reveal major, previously unreported
differences in the naïve and memory CMV speciﬁc T-cell
repertoire but suggest that atypical epitopes may indeed be
important. Indeed, in a clinical trial of CB-derived virus-
speciﬁc T-Cells, one patient with active CMV viremia
received three doses of virus-speciﬁc T-Cells and was ulti-
mately able to clear the virus with detectable CMV-speciﬁc
T-Cells in the peripheral blood of the patient post-ﬁrst T-Cell
infusion.
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Background: Patients (pts) with acute leukemia are
increasingly receiving RIC allo-SCT. Previously we have
shown that peripheral blood (PB) or bone marrow (BM)
grafts are associated with similar outcome after RIC MRD or
MUD allo-SCT for AML in remission. In current analysis we
have expanded study populations to include transplants
until 2012 from matched and mismatched (MM) donor in
both AML and ALL at any disease stage at transplant.
Methods: Pts who underwent related or unrelated donor RIC
PB or BM transplant from Jan 2000 to Dec 2012 were
included in the study. All unrelated donors were HLA-allele
matched (10/10) or 1 allele MM (9/10) (-A, -B, -C, DRB1,
-DQB1). Survival (OS) and DFS were estimated by Kaplan-
Meier. Relapse incidence (RI), NRM, engraftment, acute and
chronic GVHD were calculated using cumulative incidence
(CInc) methods. Risk factors for outcomes were analyzed by
Cox and Fine models.
Results: 837 pts transplanted with BM and 9011 with PB
after RIC regimens were compared. Among related donor,
5139 (52.6%) were geno-identical (BM¼388, PB¼4751) and
538 (5.5%) were MM (BM¼122, PB¼416). Of unrelated
donor, 3114 (31.6%) were 10/10 matched (BM¼220,
PB¼2894) and 1057 (10.7%) were 9/10 MM (BM¼107,
PB¼950). Median follow-up was 27 months for entire
cohort (BM 29, PB 27; p¼0.27). 8777 (89.1%) pts had AML
(BM¼702, PB¼8075) and ALL 1071 (10.9%) (BM¼135,
PB¼936). 5668 pts were in CR1 (BM¼475, PB¼5193), CR2+
1690 (BM¼177, PB¼1513) and 2490 had advanced disease
(BM¼185, PB¼2490). There were no statistically signiﬁcant
differences in cytogenetic risk categories among AML or ALL
for pts receiving BM or PB allo-SCT. CInc of engraftment was
lower in BM pts, 88 vs. 95.4% (p<0.0001). Grade II-IV
aGVHD was lower in BM (19.4%) vs. 23.8% in PB (p¼0.005).
cGVHD was more frequent after PB (36.2 vs. 28.9%,
p¼0.0003). RI was signiﬁcantly higher among BM recipients
(43 vs. 35.4%, p¼0.0004) whereas NRMwas not signiﬁcantly
different with the either stem cell source (p¼0.19). In
multivariate analysis, OS (HR 0.90, 95% CI 0.81-1.0; p¼0.05)
and DFS (HR 0.88, 0.79-0.97; p¼0.01) were higher in pts
transplanted with PB compared to BM. Furthermore, PB was
also associated with decreased risk of relapse (HR 0.78, 95%
CI 0.69-0.88; p¼0.00006).NRM was not signiﬁcantly
different between BM and PB and cGVHD was signiﬁcantly
lower after BM grafts (HR 1.38, 95%CI 1.18-1.61; p¼0.00008).
When analyzing separately ALL and AML pts, multivariate
analysis showed PB grafts was signiﬁcantly associated
higher LFS for AML, but not for ALL and no signiﬁcant dif-
ference OS between PB and BM groups.
Conclusion: Despite the limitation of a retrospective reg-
istry based study, our study shows that transplants with PB
from matched or MM related or unrelated donor after RIC
give the best outcomes. However, increased risk of cGVHD
after PB grafts is alarming and long-term follow-up is
needed to see if cGVHD related deaths might increase risk of
late NRM.35
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Background: Patients with metastatic or recurrent/re-
fractory sarcomas have a dismal prognosis with 5-year sur-
vival of 10-20%. IGF1R (insulin-like growth factor-1 receptor)
is highly expressed on themajority of sarcomas. Clinical trials
with anti-IGF1R antibody in patients with refractory Ewing
sarcoma (EWS) have produced low response rates (10-14%),
which exemplify the need to develop alternative new ther-
apies toward this target.
Objective: We hypothesize that IGF1R chimeric antigen re-
ceptor (CAR) Tcellswill bemore effective than antibodyalone
against IGF-1R+ sarcomas even at low levels of expression.
Methods: To test our hypothesis, we transfected peripheral
blood lymphocytes from 6 healthy donors and 3 sarcoma
patients with Sleeping Beauty (SB) transposons encoding
IGF1R CAR with a 4-1BB signaling domain and GFP
(IG) or GFP:Zeocin fusion gene (IGZ) and SB100X transposase-
expressing plasmids and selected for GFP or drug resistance.
Results: 51Cr-release assays demonstrated the cytotoxicity of
IGF-1R CAR T cells against a panel of IGF-1R+ sarcoma cellFig 1. In vitro and In vivo anti-sarcoma activity of IGF1R and ROR1 CART cells. (A) Cy
cells (7.5x105) were i.v. injected into NSG mice for 5 days, treated with mockH IGF1R
tumor control on day 11, 17, 24, 31 and 38, (C) Survival beneﬁt of CAR T cells in a local s
untreated or treated with mock, IGF1R CAR (IGZ) and ROR1 CAR (RGZ)T cells on daylines including 2 osteosarcoma (OS), 3 alveolar rhabdomyo-
sarcoma (ARMS), 2 embryonialrhabdomyosarcoma (ERMS), 1
ﬁbrosarcoma (FS), and 1 EWS. CAR+ T cells were not cytotoxic
for IGF1R- K562 erythroleukemia and Daudi lymphoma cells
and unmodiﬁed T cells did not kill IGF1R+ target cells (Fig.
1A). CAR+ T cells also killed human IGF1R cDNA transfected
mouse ﬁbroblast cells derived from IGF1R knockout mice
but not parental cells. In addition, we also demonstrated
expression of the alternative target ROR1(receptor tyrosine
kinase-like orphan receptor 1) in 13 of 17 sarcoma cell
lines tested as it has been shown that ROR1 is highly
expressed in certain types of cancer but not in normal
adult tissues. Multiplex cytokine assays showed that both
IGF1R and ROR1 CAR T cells produced high levels of IFN-g,
TNF-a and IL-13 in an antigen-speciﬁc manner.
Furthermore, both IGF1R and ROR1 CAR T cells were
generated from 3 sarcoma patients and were shown to
release signiﬁcant amounts of IFN-g in response to
stimulation with cultured allogeneic sarcoma lines. The in
vivo adoptive transfer of both IGF1R and ROR1 CAR T cells
derived from a sarcoma patient signiﬁcantly (p<0.02)
reduced tumor growth and prolonged the survival of
animals in both pre-established, systemic (i.v.) and local
(i.p.) osteosarcoma xenograft models (Fig. 1B and 1C).
Conclusion: These data indicate that both IGF1R and ROR1
can be effectively targeted by CAR T cells and that such CAR T
cells may be useful in the treatment of metastatic or re-
fractory sarcomas.totoxicity assays, (B) Anti-sarcoma activity in a systemic model, SaOS2-fﬂucN
CAR (IGZ) and ROR1 CAR (RGZ)T cells (1x107) on day 6 and 9, and imaged for
arcoma model, SaOS2-fﬂucN (3x105) cells were i.p. injected in NOD/SCID mice,
3, 5 and 7 and monitored for survival.
